Table 2 Spirometry, quadriceps strength, functional exercise capacity, physical activity levels and blood serum parameters in patients during a respiratory exacerbation and in stable patients
From: Impact of exacerbations of cystic fibrosis on muscle strength
Exacerbation | ||||
|---|---|---|---|---|
During exacerbation | Follow-up | Stable | ||
(n = 19) | (n = 17) | (n = 10) | ||
Day 1 | Day 14 | Day 40 | ||
Spirometry | ||||
FEV1 (L) | 2.1 ± 0.9**,# | 2.7 ± 1.1# | 2.4 ± 1.0 | 2.8 ± 1.0 |
FEV1 (%pred) | 55 ± 19**,## | 69 ± 25# | 61 ± 23 | 72 ± 22 |
FVC (L) | 3.5 ± 1.0** | 4.0 ± 1.2 | 3.7 ± 1.2 | 4.1 ± 0.8 |
Quadriceps strength and functional exercise capacity | ||||
Twqpot (N) | 140 ± 42 | 140 ± 47 | 129 ± 35 | 158 ± 40 |
MVC (N) | 378 ± 128 | 369 ± 119 | 353 ± 109 | 456 ± 157 |
6MWD (m) | / | 694 ± 89§ | 698 ± 84§ | 786 ± 111 |
Physical activity | ||||
Daily steps (n) | 4654 ± 2929#,§ | 7174 ± 4423 | 7414 ± 2810 | |
Time > 4.8 METs (min) | 6 [2-17] # | 14 [4–40] | 11 [6–35] | |
Hematological parameters, testosterone and systemic inflammation | ||||
Hemoglobin (g/dL) | 13.9 ± 1.5 | 13.7 ± 1.6 | 13.8 ± 1.4 | 14.8 ± 1.2 |
Blood platelets (x109/L) | 314 ± 109* | 287 ± 104 | 339 ± 87 | 250 ± 63 |
Testosterone (in men) (ng/dL) | 249 [148–281] | 354 [251–442] | 256 [209–363] | / |
WBC count (x109/L) | 12.6 ± 4.3**,#,§ | 8.6 ± 3.1 | 9.9 ± 2.3§ | 7.4 ± 2.2 |
Neutrophil count (x109/L) | 8.6 ± 3.0**,§ | 5.2 ± 2.4 | 7.1 ± 2.4§ | 4.7 ± 1.8 |
CRP (mg/L) | 13 [8–48]**,§ | 3 [0–5] | 9 [7-18] § | 2 [0–7] |